Ruti Aga banned for six years: a knee injury, a forged prescription and the end of a career

The Athletics Integrity Unit (AIU) announced on Thursday that Ethiopian marathoner Ruti Aga has been banned for six years. Aga, 32, won the 2026 Tokyo Marathon, and her case began as an ordinary doping matter and ended on a forged medical prescription. According to the AIU statement, the sanction has two parts: two years for the presence of a prohibited substance and four years for tampering with the investigation. Together they make six years, counted from 10 September, the date her provisional suspension took effect. Time served under provisional suspension is credited against the ban, so the backdating is a procedural benefit, not a real reduction. The factual trigger is that a sample taken after she won a half marathon in China in March returned an adverse finding for methylprednisolone. The AIU statement does not disclose the race, the winning time or the quality of the field, so no conclusion can be drawn about the performance itself. All that is established is that the sample, collected after the win, contained a prohibited substance. Aga's explanation was a knee injury. Intra-articular or peri-articular glucocorticoid injections for knee inflammation are standard sports-medicine practice in distance runners. The explanation is medically plausible, and that is precisely the irony of the case. The defence that genuinely existed could have been proven with genuine records. Instead, the paperwork was fabricated. A technical clarification is necessary here, because several reports have described methylprednisolone as a prohibited steroid. That is imprecise. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, not an anabolic steroid (class S1). Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. Out-of-competition therapeutic use is not in itself a violation. The direct consequence of that classification is that the entire case turned not on use of a substance but on route of administration and on timing relative to the competition. A road race's testing window opens at 23:59 the night before the race, so an injection given days earlier can still be caught. A legitimate treatment with bad timing becomes a violation; the same treatment with clean records and correct timing is no case at all. But the records were not clean. What the investigation surfaced is a failure at three independent levels. First, the doctor who issued the prescription was a family member with no medical registration. Second, the clinic named on the prescription did not exist. Third, the individual claimed to have used an old prescription pad from a former workplace, and the clinic explicitly disowned that claim. That is why the four-year sanction falls under tampering. The charge rests not only on the document but also on statements made in the investigation interview, meaning information given under questioning became part of the dispute. The outcome is that the defence that could have worked, namely the injury treatment, the route, the timing and, if necessary, a therapeutic use exemption, was destroyed. The forged prescription did not serve as a defence; it became the evidence that killed one. An athlete operating inside a properly structured set-up had two routes: obtain a TUE for the knee injection, or observe WADA's route-specific washout period. Neither happened. That points to the absence of a credentialed team physician; had real records existed, there would have been no need to forge a prescription. Measured in career terms, the weight of the sanction is obvious. Aga won the 2026 Tokyo Marathon and finished second three times at World Marathon Majors. According to reported figures, her personal bests are around 2:18:34 (Berlin 2026) and 2:20:40 (Tokyo 2026), although the AIU statement gives no times. At 32, a six-year ban removes her from the 2028 Olympic cycle entirely, and she would be roughly 38 on return. Ethiopian women's marathon depth is such that even a 2:18 performer is not automatically selected for the national team. A 38-year-old returnee carrying a doping record therefore has, in practical terms, no route back. In other words, this is not a six-year ban; it is a lifetime ban for elite purposes. One thing survives: the 2026 Tokyo title. The violation is anchored to a later race, and absent proof of earlier use, results before that date are not automatically annulled. The AIU did not state the scope of disqualification, but standard practice voids the result and prize money from the competition at which the sample was collected. The most consequential part of this case is not the substance but the system around it. A doctor who is a family member, no registration, no clinic that exists: that is not a filing error, it is the signature of an athlete working without a credentialed team physician. That medical-governance gap is systemic across East African road-running entourages, and the knee injury sits at the root of the whole episode. The economics are part of it. Aga's post-2026 pattern was selective Major racing plus Asian label races: few starts, high appearance fees. China's label circuit is a major income tier for East African marathoners between Majors, and it is now among the AIU's highest-volume testing grounds. The appearance-fee economy and the testing economy are colliding in the same races. On the rules, the architecture of the sanction is standard. Two years for presence, consistent with specified-substance cases, and four years for tampering, the standard Code sanction. The arithmetic implies the panel did not accept a no-significant-fault mitigation, which would otherwise have reduced the presence sanction. A broader argument remains open: six years for a substance with no proven endurance benefit strikes many experts as disproportionate, and the case will be cited as evidence of heavy enforcement against African road runners. An appeal window to the Court of Arbitration for Sport is open, typically about 21 days from the reasoned decision, but a document-based forgery finding is hard to overturn, so the practical value of an appeal is low. The bigger point is that tampering has become the AIU's most common second charge in road-running cases. The enforcement frontier has shifted from detection to document verification. Aga's case is not an outlier; it belongs to a recognisable category in which a fabricated explanation is layered on top of an underlying substance violation.